

# Identification of HDAC10 Inhibitors that Modulate Autophagy-Related Proteins in Transformed Cells

Patrik Zeyen<sup>1,#</sup>, Yanira Zeyn<sup>2#</sup>, Daniel Herp<sup>3</sup>, Fereshteh Mahmoudi<sup>1</sup>, Talha Z. Yesiloglu<sup>1</sup>, Frank Erdmann<sup>1</sup>, Matthias Schmidt<sup>1</sup>, Dina Robaa<sup>1</sup>, Christophe Romier<sup>4</sup>, Johannes Ridinger<sup>5,6</sup>, David W. Christianson<sup>7</sup>, Ina Oehme<sup>5,6</sup>, Manfred Jung<sup>3</sup>, Oliver H. Krämer<sup>2,\*,#</sup> and Wolfgang Sippl<sup>1,\*,#</sup>

<sup>1</sup> Institute of Pharmacy, Martin-Luther University of Halle-Wittenberg, Wolfgang-Langenbeck-Str. 2-4, 06120 Halle/Saale, Germany

<sup>2</sup> Institute of Toxicology, Johannes-Gutenberg University of Mainz, Obere Zahlbacher Str. 67, 55131 Mainz, Germany

<sup>3</sup> Institute of Pharmaceutical Sciences, Albert-Ludwigs University of Freiburg, Albertstraße 25, 79104 Freiburg, Germany

<sup>4</sup> Université de Strasbourg, CNRS, INSERM, Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), Département de Biologie Structurale Intégrative, 67404 Illkirch Cedex, France

<sup>5</sup> Hopp Children's Cancer Center Heidelberg (KiTZ), 69120 Heidelberg, Germany

<sup>6</sup> Clinical Cooperation Unit Pediatric Oncology, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), 69120 Heidelberg, Germany

<sup>7</sup> Roy and Diana Vagelos Laboratories Department of Chemistry University of Pennsylvania Philadelphia, PA 19104-6323, USA

# contributed equally to the work

\* equal last author contributions

‡ correspondence to okraemer@uni-mainz.de and wolfgang.sipl@pharmazie.uni-halle.de

## **Abstract**


Histone deacetylases (HDACs) are a family of 18 epigenetic modifiers that fall into 4 classes. Histone deacetylase inhibitors (HDACi) are valid tools to assess HDAC functions. HDAC6 and HDAC10 belong to the class IIb subgroup of the HDAC family. The targets and biological functions of HDAC10 are ill-defined. This lack of knowledge is due to a lack of specific and potent HDAC10 inhibitors with cellular activity. Here, we have synthesized and characterized piperidine-4-acrylhydroxamates as potent and highly selective inhibitors of HDAC10. This was achieved by addressing the acidic gatekeeper residue Glu274 of HDAC10 with a basic piperidine moiety that is mimicking the interaction of the oligoamine substrate of HDAC10. Promising candidates were selected based on their specificity by in vitro profiling using recombinant HDACs. The most promising HDAC10 inhibitors **13b** and **10c** were tested for specificity in acute myeloid leukemia (AML) cells with the FLT3-ITD oncogene. By immunoblot experiments we assessed the hyperacetylation of histones and tubulin- $\alpha$ , which are class I and HDAC6 substrates, respectively. As validated test for HDAC10 inhibition we used flow cytometry assessing autolysosome formation in neuroblastoma and AML cells. We demonstrate that this is not a consequence of apoptosis and **13b** and **10c** are not toxic for normal human kidney cells. These data unravel that **13b** and **10c** are micromolar inhibitors of HDAC10 with high specificity. Thus, our new HDAC10 inhibitors are tools to identify the downstream targets and functions of HDAC10 in cells.

*Keywords: Histone deacetylases (HDAC), HDAC10, drug design, ligand docking, chronic lymphoid leukemia, acute myeloid leukemia (AML), autophagy, lysosomes.*

## Introduction

Histone deacetylases (HDACs) are epigenetic modifiers that control the acetylation of histones and non-histone proteins. This posttranslational modification regulates a plethora of physiologically relevant processes including cell proliferation, survival, genomic integrity, and protein homeostasis. Accordingly, HDACs are often dysregulated in transformed cells.<sup>1, 2</sup> HDACs are grouped into 4 classes, class I (HDAC1, HDAC2, HDAC3, HDAC8), class IIa (HDAC4, HDAC5, HDAC7, HDAC9), class IIb (HDAC6, HDAC10), class III (sirtuins SIRT1-7), and class IV (HDAC11)<sup>1, 2</sup> (**Fig. 1**). Sirtuins use NAD<sup>+</sup> for the deacetylation of acetyl-lysine residues and all other HDACs catalyze this reaction via a Zn<sup>2+</sup> located within their catalytic pockets.

3



**Figure 1:** Zn<sup>2+</sup>-dependent HDACs and examples of histone deacetylase inhibitors (HDACi). The catalytic domain(s) in the different Zn<sup>2+</sup>-dependent HDACs are represented in color. Examples of developed inhibitors are named.


Meanwhile, the catalytic domains display a high degree of homology. Accessory domains, that mainly execute regulatory functions, are variable in structure. HDAC6 and HDAC10 belong to the class IIb subgroup. While both catalytic domains are active in HDAC6, HDAC10 has an active domain and an inactive domain. The benzamide derivative entinostat (MS-275), the aliphatic fatty acid valproic acid (VPA), and the two hydroxamic acid derivatives panobinostat (LBH589) and vorinostat (SAHA) are class-specific and pan-HDACi (**Fig. 2**).

HDAC inhibitors (HDACi) have been developed to address diseases which have been linked to overactive and overexpressed HDACs. The FDA has approved four pan-HDACi as salvage therapy for the treatment of cutaneous T-cell lymphoma and multiple myeloma. However, the lack of selectivity of these clinically approved drugs frequently causes dose limiting side-effects.<sup>1, 2, 4, 5</sup> The inhibitory mechanism of HDACi relies on a complex formation of their warheads (e.g., hydroxamic acid, thiol) with the Zn<sup>2+</sup> ion in the catalytic pockets of HDACs.<sup>3</sup>

HDAC10 has unique functions and structural features, such as an active and an inactive deacetylase domain (**Fig. 1**). Recently, the substrate specificity of HDAC10 was extended: HDAC10 was discovered to be a polyamine deacetylase. Thus, HDAC10 has important non-protein, non-lysine deacetylase activity. Polyamines are regulators of protein homeostasis through macroautophagy (hereafter termed autophagy).<sup>6-8</sup> This evolutionarily conserved pathway is activated upon starvation but also upon other types of stress, including DNA replication stress and DNA damage.<sup>9</sup> During autophagy, cytoplasmic proteins and structures are embedded in autophagosomes that are subsequently digested with the help of lysosomal components.<sup>10</sup> In Neuroblastoma cells, the catalytic activity of HDAC10 is necessary for the process of autophagy (also termed autophagic flux) and inhibition of HDAC10 can cause an accumulation of autolysosomes.<sup>6</sup> Moreover, an inhibition of HDAC10 causes an accumulation of lysosomes in neuroblastoma cells.<sup>11</sup> In cervix carcinoma cells, a genetic knockout of HDAC10 disrupts chaperone-mediated autophagy (CMA). This process depends on lysosome-associated protein type 2A and promotes the lysosomal degradation of the glycolytic enzyme GAPDH.<sup>12</sup>

There is particularly little knowledge about the roles of HDAC10 in leukemia.<sup>7</sup> It was shown that an overexpression of HDAC10 in cultured chronic lymphoid leukemia (CLL) and mantle cell lymphoma cells (transformed B lymphocytes) caused cell cycle arrest and ultimately apoptosis.<sup>13</sup> Whether this is due to

unphysiological levels of HDAC10 is currently not known. Analysis of HDAC expression in 32 primary CLL cells and normal lymphoid cells revealed that HDAC1, HDAC3, HDAC6, HDAC7, HDAC9, HDAC10, SIRT1, and SIRT6 are overexpressed in CLL cells. The high expression of these enzymes was associated with advanced disease and poor prognosis.<sup>14, 15</sup> A further study compared 200 CLL patient samples at diagnosis and after relapse with normal B cells. This work revealed an association of poor prognosis with an overexpression of HDAC7 and HDAC10 and a reduced expression of HDAC6 and SIRT3 in CLL cells.<sup>16</sup> While the impact of HDACs on the clinical course of CLL seems to be complex, both studies agree on a linkage between HDAC10 and worse prognosis. Since a full-body genetic elimination of HDAC10 in mice is not toxic for normal tissues,<sup>17</sup> HDAC10 inhibition could be a safe strategy to combat tumor cells that depend on it. To date, nothing is published about the relevance of HDAC10 in other types of leukemia. HDAC10 inhibitors can elucidate the biological relevance of this enzyme and whether it is a valid pharmacological target in disease. However, only a few inhibitors that target HDAC10 have been identified to date (**Fig. 2**).<sup>18</sup> For example, tubastatin A and recently reported hybrid HDAC6/8/10 inhibitors based on the tubastatin-A scaffold (**1b**).<sup>19</sup> TH34 (3-(*N*-benzylamino)-4-methylbenzhydroxamic acid) is a pan-HDAC6/8/10 inhibitor that was recently reported by us.<sup>20</sup> HDACi containing a 2-(oxazol-2-yl)phenol moiety were also reported to inhibit HDAC1, HDAC6, and HDAC10.<sup>21</sup> Thus, HDAC10 inhibitors with selectivity over the class I isozymes are available but the main challenge lies in getting selectivity over the other class IIB member HDAC6.



**Figure 2.** Structures of discussed HDAC inhibitors.

## Results and Discussion


### *Synthesis and in vitro testing of novel inhibitors*


Based on the observation that TH34 is an inhibitor of HDAC10, but equally active on HDAC6,<sup>20</sup> we started with the synthesis of a first series of benzhydroxamic acid derivatives that bear a basic amine in the capping group. The selection of capping groups as well as the position of the basic amine was guided by docking the compounds into the available X-ray structures of *danio rerio* HDAC10 (drHDAC10).<sup>18, 22, 23</sup>

Introducing a methylene-group between the benzhydroxamic core and the basic amine resulted in hits that showed a salt-bridge to the gatekeeper residue Glu274 of HDAC10 (**Fig. S1, Supplementary Information**) and were therefore prepared as described in the Methods section.

**Table 1:** Chemical structures and inhibition of drHDAC10.


ID	structure	IC <sub>50</sub> drHDAC10 [nM]
----	-----------	--------------------------------







**Tubastatin A**



220 ± 20

To evaluate the HDAC selectivity profile, we tested all synthesized compounds against drHDAC10 as well as human HDACs 1, 6, and 8 *in vitro*. In case of drHDAC10 we recently developed an enzymatic *in vitro* assay that was used in the current study.<sup>24</sup> Compound **6a**, bearing an *N*-piperidinomethylene capping group, showed only weak HDAC10 inhibition and also very low activity against other HDACs. Meanwhile, replacement of the piperidine ring of **6a** with an *N*-methylpiperazine moiety yielded compound **6b** which was found to a potent inhibitor against drHDAC10 ( $IC_{50}$  43 ± 7 nM). Substitution of the secondary amino group with different arylmethyl moieties similarly yielded compounds with strong inhibitory activity against drHDCA10 (**4a-4c**). Among these benzhydroxamic acid derivatives, **4c** bearing a 3-thienylmethyl capping group showed the strongest HDAC10 inhibition (**Table 1**) with an  $IC_{50}$  of 24 ± 5 nM. The 2-thienylmethyl analogue **4b** showed a slight decrease in the inhibitory activity ( $IC_{50}$  of 106 ± 28 nM). **4a** with a simple benzyl capping group was also found to be a potent inhibitor of drHDAC10 ( $IC_{50}$  of 37 ± 10 nM).

In addition we designed and prepared piperidine-4-acrylhydroxamic acid derivatives bearing different arylethylene or arylmethylene capping groups. These compounds were structurally modified by using docking studies in crystal structure of drHDAC10. Docking of these derivatives into the crystal structure of HDAC10 showed that they are able to adopt a similar binding orientation as observed for the *N*8-acetylspermidine analogue inhibitor with an overlap of their basic amino group (**Fig. S2 and S3, Supplement**). The piperidine-4-acrylhydroxamic acid derivatives were able to undergo extensive interactions in the HDAC10 binding pocket which explain their strong inhibitory activity on this isoform


(Fig. 3). The hydroxamate moiety chelates the catalytic zinc ion in a bidentate fashion and shows the typical hydrogen bond interactions with the neighbouring histidine and tyrosine residues. The protonated amine of the piperidine is placed between Asp94 and the gatekeeper residue Glu274 exhibiting a salt bridge interaction. Meanwhile, the capping groups displayed different interactions with the amino residues at the edge of the binding pocket due to the use of linkers of distinct lengths.

Except for **10f** and **10g**, which carry a *p*-tolylmethylene or biphenyl capping group, all herein described piperidine-4-acrylhydroxamic acid derivatives exhibited submicromolar inhibition of HDAC10, with the phenethyl derivative **10a** showing the highest inhibitory potency ( $IC_{50}$   $11 \pm 1$  nM). A consistent impact of the linker length on the compounds' activity could not be observed. While the benzyl and *p*-tolylmethylene derivatives (**10e** and **10f**, respectively) showed a significant decrease in the HDAC10 inhibitory activity, the *m*- and *p*-chlorobenzyl analogues (**10d** and **13c**, respectively) showed strong HDAC10 inhibition ( $IC_{50}$   $60 \pm 5$  nM and  $33 \pm 3$  nM, respectively).


A potent drHDAC10 inhibition was also found for compounds **10b**, **10c**, **13a** and **13b**, which all bear a bicyclic aromatic moiety as a capping group with either a methylene or ethylene spacer to the basic amino acid group. **10c** has, just as **10e**, a methyl linker between the tertiary amine and the capping group, but the aromatic system (naphthyl) is significantly larger so that a  $\pi$ - $\pi$  stacking with Trp205 may occur. **10b** has an ethyl linker and an indole cap group, which shows, that a combination of ethyl linker and bigger cap group can also lead to potent inhibitors. **13b** and **13a** show a slightly decreased inhibitory activity against drHDAC10 compared to **10b**. This shows that the ethyl linker in combination with an indole capping group is favourable compared to a methyl linker in combination with an *N*-methylindole (**13b**) or benzothiophene capping group (**13a**). As exemplified by the predicted binding modes of **10c** and **13b** (Fig. 3) in drHDAC10 (PDB ID: 5TD7; A and B) and the humanized form of drHDAC10 (PDB ID 6VNQ), it can be observed that the bicyclic capping group is situated above Phe204 where it undergoes  $\pi$ - $\pi$  stacking interactions. Additional interactions include the essential  $Zn^{2+}$  coordination via the

hydroxamate group, as well as the commonly observed hydrogen bond interactions of the hydroxamic acid warhead with the side chains of His136, His137 and Tyr307. The protonated piperidine-NH forms a salt-bridge interaction to the gatekeeper amino acid Glu274 as well as cation- $\pi$  interaction with Trp205.

A)




B)



C)

D)



**Figure 3:** Obtained docking poses for selected HDAC10 inhibitors in the catalytic pocket of drHDAC10 (PDB ID: 5TD7; A and B) and the humanized form of drHDAC10 (PDB ID 6VNQ; C and D)). A) Binding mode of **13b** (slate blue sticks) in drHDAC10 (PDB ID: 5TD7); B) Binding mode of **10c** (pink sticks) in drHDAC10 (PDB ID: 5TD7); C) Binding of **13b** (slate blue sticks) in the humanized form of drHDAC10 (PDB ID 6VNQ); D) Binding of **10c** (pink sticks) in the humanized form of drHDAC10 (PDB ID 6VNQ). The Zn ion is shown as cyan sphere and water molecules as red spheres. Yellow dashed lines depict hydrogen bond interactions, cyan dashed lines metal chelation, green dashed lines cation- $\pi$  interactions and blue-dashed lines  $\pi$ - $\pi$  interactions.

In summary, it can be stated that the piperidine-4-acrylhydroxamic acid scaffold is able to undergo the desired interactions with the  $\text{Zn}^{2+}$  ion and the gatekeeper residue Glu274. The different orientations of

the capping groups show that additional interactions can take place in the outer part of the substrate binding tunnel which might influence the inhibitory activity against drHDAC10.

**Table 2:** In vitro selectivity of the synthesized HDAC10 inhibitors.

ID	hHDAC1	hHDAC6 IC <sub>50</sub> [nM]	hHDAC8 IC <sub>50</sub> [nM]
<b>4a</b>	49 % @ 10 μM 19 % @ 1 μM	210 ± 26	3500 ± 520
<b>4b</b>	68 % @ 10 μM 15 % @ 1 μM	158 ± 21	3200 ± 410
<b>4c</b>	50 % @ 10 μM 16 % @ 1 μM	177 ± 28	1900 ± 340
<b>6a</b>	n.d.	n.d.	5 % @ 1 μM
<b>6b</b>	54 % @ 10 μM 6 % @ 1 μM	280 ± 25	2400 ± 210
<b>10a</b>	16 ± 9 μM	4400 ± 400	250 ± 50
<b>10b</b>	54 % @ 10 μM 7 % @ 1 μM	4800 ± 1100	420 ± 55
<b>10c</b>	3.0 ± 0.2 μM	3700 ± 450	470 ± 70
<b>10d</b>	67 % @ 10 μM 24 % @ 1 μM	83 % @ 10 μM 40 % @ 1 μM	2500 ± 260
<b>10e</b>	62 % @ 10 μM 12 % @ 1 μM	89 % @ 10 μM 34 % @ 1 μM	n.d.
<b>10f</b>	n.d.	n.d.	n.d.
<b>10g</b>	56 % @ 10 μM 22 % @ 1 μM	72 % @ 10 μM 29 % @ 1 μM	91 % @ 10 μM 54 % @ 1 μM
<b>13a</b>	66 % @ 10 μM 29 % @ 1 μM	1400 ± 140	1300 ± 170
<b>13b</b>	67 % @ 10 μM 12 % @ 1 μM	2420 ± 530	920 ± 170
<b>13c</b>	9 ± 1 μM	430 ± 50	950 ± 260
<b>Entinostat (MS-275)</b>	0.93 ± 0.1 μM	n.i.	n.i.
<b>Tubastatin A</b>	1.91 ± 0.42 μM	34 ± 17	1440 ± 120

n.d. = not determined; n.i. = no inhibition

### *In vitro selectivity testing*

To evaluate the HDAC selectivity profile, we tested all synthesized compounds against drHDAC10 as well as human HDACs 1, 6, and 8 in vitro. The benzhydroxamic acids show good hHDAC1 and hHDAC8 selectivity. The top hHDAC1 selectivity of this class was observed for **4c** with a selectivity index (SI) of 417, the lowest selectivity was observed for **4b** with an SI of 85. For the hHDAC8 selectivity, the SI are between 30 for **4b** and 94 for **4a**. The benzhydroxamic acid derivatives barely show selectivity against hHDAC6, only **4a**, **4c** and **6b** showed a slight selectivity with an SI of 17, 20 and 9; respectively. Since HDAC6 is structurally related to HDAC10, one of the main tasks for the development of HDAC10 inhibitors is to achieve good selectivity against hHDAC6. This has been achieved with the piperidine-4-acrylhydroxamic acid scaffold. **10a** shows a strong selectivity with an SI of 395 against hHDAC6, 1454 against hHDAC1. In addition to the strongest drHDAC10 inhibition, **10a** also shows the highest selectivity against hHDAC1 and hHDAC6. In addition, a good hHDAC8 selectivity with an SI of 23 for **10a** is observed. Most of the piperidine-4-acrylhydroxamic acid derivatives are weak HDAC6 inhibitors with the exception of **13c** ( $430 \pm 50$  nM).

### *Cellular testing*

Next, we tested the specificity of the most promising HDAC10 inhibitors from the in vitro characterization (**10c** and **13b**) in cells. An increased lysosomal compartment has been identified as a marker for HDAC10 inhibition in neuroblastoma cells.<sup>11</sup> Compounds with potent drHDAC10 inhibitory activity and good selectivity against hHDAC1, hHDAC6 and hHDAC8, were first tested in SK-N-BE(2)-C neuroblastoma cells. **13b** and **10c** induced the expansion and acidification of the lysosomal compartment, as measured using the pH-dependent LysoTracker DND-99 fluorescent probe (**Fig. S4**

Supplementary Information). This increase of the lysosomal compartment is in line with the described role for HDAC10 in lysosomal homeostasis and autophagy in neuroblastoma.<sup>6,11</sup>

Since there are no data on a possible role for HDAC10 in autophagy regulation in leukemic cells, we applied **13b** and **10c** to MV4-11 cells (**Fig. 4**). These cells are derived from a childhood leukemia and carry an internal tandem duplication in the FMS-like tyrosine kinase (FLT3-ITD). This subtype of acute myeloid leukemia (AML) cells is characterized by poor prognosis and relapse.<sup>11, 25</sup> The dye cyto-ID is incorporated into and therefore a marker of autophagic vesicles (pre-autophagosomes, autophagosomes, phagolysosomes),<sup>26</sup> which have been shown to accumulate in neuroblastoma cells with inhibited HDAC10.<sup>6</sup> Flow cytometry illustrated that **13b** and **10c** significantly induced the accumulation of cyto-ID positive vesicles in MV4-11 cells (**Fig. 4A**). This encouraged us to further analyze the specificity of **13b** and **10c** in cells.


The enzymatic *in vitro* testing described above measured only weak activity of **13b** and **10c** against HDAC1. Immunoblots with whole cell lysates from MV4-11 cells coherently showed that 2-15  $\mu\text{M}$  **13b** and **10c** did not induce a significant accumulation of acetylated histone H3 (**Fig. 4A**), which is the prototypical target of class I HDACs.<sup>27</sup> This indicates that class I HDACs are not substantially affected by **13b** and **10c** in these cells. 5  $\mu\text{M}$  of the class I HDACi entinostat (MS275, used as positive control, **Fig. 2**) induced a highly significant accumulation of acetylated histone H3 (**Fig. 4D**).

The accumulation of acetylated tubulin- $\alpha$  serves as a marker for the inhibition of HDAC6.<sup>27, 28</sup> We used the recently identified highly selective inhibitor of HDAC6, marbostat-100, as a positive control for HDAC6 inhibition.<sup>28</sup> Compared to 0.5  $\mu\text{M}$  marbostat-100, which enhanced tubulin acetylation 1324-fold on average compared to non-treated cells, 15  $\mu\text{M}$  **13b** and **10c** induced the acetylation of tubulin 36-80 fold and this effect did not reach significance (**Fig. 4B,4C**). These data are in line with the above-described *in vitro* data (**Table 1, 2**). The impact of **13b** and **10c** on the accumulation of cyto-ID positive


vesicles was not associated with a loss of HDAC10. We rather noted slightly increased levels of HDAC10 upon its inhibition (**Fig. 4B**). Moreover, we noted no change of GAPDH levels (**Fig. 4B**). This finding disfavors that **13b** and **10c** promote chaperone-mediated autophagy (CMA) in MV4-11 cells. Since CMA was induced by a genetic elimination of HDAC10 in solid tumor-derived cells,<sup>12</sup> the unchanged expression of HDAC10 in **13b** and **10c** treated MV4-11 cells can explain why GAPDH remained unchanged.




A




B



C



D



**Figure 4: 13b and 10c preferentially inhibit HDAC10 in leukemic cells.**

A: MV4-11 cells were treated with increasing concentrations of **13b** and **10c**, from 2-15  $\mu\text{M}$  for 24 h; Ctrl, solvent treated samples. 10  $\mu\text{M}$  chloroquine were added to all samples to facilitates the detection of cyto-ID positive vesicles by reduced lysosomal acidification; n = 3. Statistical significance was determined using Two-way ANOVA, \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\*\* $p < 0.0001$ .

B: MV4-11 cells were incubated with 2-15  $\mu\text{M}$  **13b** and **10c**, 5  $\mu\text{M}$  MS-275, or 0.5  $\mu\text{M}$  marbostat-100 (MARB-1) for 24 h (Ctrl, solvent control). Immunoblot was done as indicated, with  $\beta$ -actin as loading control; n = 2.

C: Quantification of the immunoblots **B** using Image Studio Lite (LI-COR Biosciences); n = 2.

D: MV4-11 were treated with 2-15  $\mu\text{M}$  **13b** and **10c** (Ctrl, solvent control), incubated for 24 h and subjected to flow cytometry analyses for annexin-V-FITC and propidium iodide (PI); n = 3. Two-way ANOVA, \* $p < 0.05$ .

Next, we tested whether the accumulation of autophagic vesicles upon HDAC10 inhibition is linked to apoptosis of MV4-11 cells. Early apoptosis is determined by positive annexin-V-FITC staining caused by the exposure of phosphatidylserine on the cell surface. Late apoptosis and necrosis are indicated by positive annexin-V-FITC staining as well as accumulation of propidium iodide due to the loss of the membranal integrity.<sup>29</sup> The addition of increasing doses of **13b** and **10c** did not induce apoptosis (**Fig. 4C**) compared to class I HDAC inhibition with MS-275 (**Fig. 4C**), indicating that the inhibition of HDAC10 does not induce pro-apoptotic mechanisms in MV4-11 cells.

Coherent with these data, we found that our new HDAC10 inhibitors were not toxic for human embryonic kidney-derived HEK293 cells, even at a high concentration of 50  $\mu\text{M}$  (**Table 3**).


**Table 3:** Cytotoxicity against HEK293 cells at 50  $\mu$ M inhibitor concentration.

ID	cell viability [%]
4a	77.1 $\pm$ 5.0
4b	71.6 $\pm$ 6.1
4c	81.5 $\pm$ 2.8
6a	92.6 $\pm$ 13.4
6b	86.4 $\pm$ 2.3
10a	54.4 $\pm$ 1.4
10b	77.3 $\pm$ 4.4
10c	51.6 $\pm$ 3.9
10d	88.6 $\pm$ 2.2
10e	100.9 $\pm$ 6.9
10f	104.9 $\pm$ 0.8
10g	55.0 $\pm$ 4.4
13a	88.2 $\pm$ 1.0
13b	68.2 $\pm$ 4.8
13c	84.6 $\pm$ 1.5


## Chemistry

The compounds in the present work were synthesized using the synthetic pathways outlined in **Scheme 1** and **2**. The synthetic strategy relied primarily on the synthesis of the carboxylic acid intermediates (**3a-c**, **9a-g** and **12a-c**) which were subsequently converted to the corresponding hydroxamates through the well-established method by amide coupling with *O*-(Tetrahydro-2*H*-pyran-2-yl) hydroxylamine followed by acidic deprotection.<sup>23</sup> **Scheme 1** illustrates the synthesis of target benzhydroxamate derivatives **4a-c** and **6a-b**. The respective aldehyde and ethyl 4-aminomethylbenzoate served as starting materials, where reductive amination of primary amine followed by basic hydrolysis afforded the carboxylic acid

intermediates **3a-c**. As shown in **Scheme 2**, the N-substituted-piperidineacrylic acid derivatives were obtained either via the alkylation or reductive amination of the unsubstituted piperidine derivative **7** followed by alkaline hydrolysis of the ester function to yield the carboxylic acids **9a-g**, **12a-c**. These were subsequently converted to the corresponding hydroxamates **10a-g** and **13a-c**.



**Scheme 1.** Reagents and conditions: (a) DCM, MeOH, Na(AcO)<sub>3</sub>BH, r.t, overnight; (b) i) 1M. NaOH aq., MeOH, r.t, 48h, ii) dil. HCl; (c) PyBOP, DIPEA, H<sub>2</sub>NOTHP, THF, r.t, overnight; d) catalytic. HCl, THF, r.t, overnight.



**Scheme 2.** Reagents and conditions: (a)  $K_2CO_3$ , DMF, catalytic KI; r.t., 72h; (b) THF,  $H_2O$ , LiOH.  $H_2O$ , r.t., 12h; (c) PyBOP, DIPEA,  $H_2N(OTHP)$ , THF, r.t., overnight; (d) catalytic. HCl, THF, r.t., overnight; (e) EtOH,  $Na(AcO)_3BH$ , r.t., 48h.

## Conclusion

We present here a new chemotype as HDAC10 inhibitor that we obtained by structure-based optimization. Our data reveal that piperidine-4-acrylhydroxamates inhibit HDAC10 with good selectivity and activity in vitro and in cultured cells. Consistent with previously published data in neuroblastoma cells,<sup>6</sup> we show that pharmacological modulation with hitherto unknown specific HDAC10 inhibitors modulates autophagy in aggressive FLT3-ITD positive AML cells. We further demonstrate that this is not associated with cell death. Thus, like an inhibition of HDAC6 in these and further leukemic cells,<sup>4, 30-32</sup> an inhibition of HDAC10 modulates biological processes without killing these cells. Highly consistent with these data are results from knock-out mice with a deletion of HDAC6 or HDAC10. In both cases, the animals are viable and only show altered responses upon stress.<sup>17, 33</sup> Overall, the developed HDAC10 inhibitors **13b** and **10c** are useful tools to investigate physiological functions of HDAC10 in future studies.

### **Conflict of interest**

OHK declares the patent WO2016020369A1, which covers the HDAC6 inhibitor marbostat-100 used in this article

### **Acknowledgement**

We thank Prof. S. Mahboobi, University of Regensburg, Germany, for providing marbostat-100. We thank Christina Brachetti, Andrea Piée-Staffa, and Simone Kniesa for excellent technical assistance.

### **Funding**

This work was funded by the Deutsche Forschungsgemeinschaft (DFG) SI868/22-1, project number 46995445 (to W.S.), and KR2291/9-1, project number 427404172; KR2291/12-1, project number 445785155; KR2291/14-1, project number 469954457; KR2291/15-1, project number 495271833; SFB 1361 sub-project 11, project number 393547839 to (O.H.K). The work was further funded by the Brigitte

und Dr. Konstanze Wegener Foundation (project number 65) and the Wilhelm Sander-Foundation, project number 2019.086.1 (to O.H.K).

### **Author Contributions**

P.Z. synthesized the compounds, performed the HDAC8 in vitro testing and wrote the manuscript. Y.Z. carried out cellular testing, analyzed and interpreted data, wrote parts of the manuscript, and performed statistical analysis. D.H. carried out the HDAC1,6,10 in vitro testing and analyzed data F.M. carried out analytical studies, analyzed data, and wrote the manuscript. T.Y. and D.R. did the docking and modelling studies and wrote part of the manuscript. F.E. carried out the cytotoxicity testing on human HEK293 cells. J.R. performed experiments on neuroblastoma cells, I.O. designed, analyzed experiments, and revised the paper, C.R. expressed and provided HDAC8 protein for in vitro testing. D.W.C. expressed and purified HDAC10 protein and provided it for in vitro testing. M.S., M.J., O.H.K., and W.S. designed experiments, analyzed data, and wrote the paper. O.H.K. and W.S. initiated the project and finalized the manuscript. All authors have given approval to the final version of the manuscript.

### **Declaration of Interests**

OHK declares the patent WO2016020369A1, which covers substances used in this article.

## Materials and Methods

### *General*

All materials and reagents were purchased from Sigma-Aldrich Co. Ltd. and abcr GmbH. All solvents were analytically pure and dried before use. Thin layer chromatography was carried out on aluminum sheets coated with silica gel 60 F254 (Merck, Darmstadt, Germany). For column chromatography under normal pressure silica gel 60 (0.036–0.200 mm) was used.

Final compounds were confirmed to be of >95% purity based on HPLC. Purity was measured by UV absorbance at 254 nm. The HPLC consists of an XTerra RP18 column (3.5  $\mu\text{m}$ , 3.9 mm  $\times$  100 mm) from the manufacturer Waters (Milford, MA, USA) and two LC-10AD pumps, a SPD-M10A VP PDA detector, and a SIL-HT autosampler, all from the manufacturer Shimadzu (Kyoto, Japan). For preparative tasks a XTerra RP18 column (7  $\mu\text{m}$ , 19 mm  $\times$  150 mm) from the manufacturer Waters (Milford, MA, USA) and two LC-20AD pumps were used. The mobile phase was in all cases a gradient of methanol/ water (starting at 95% water going to 5% water).

Mass spectrometry analyses were performed with a Finnigan MAT710C (Thermo Separation Products, San Jose, CA, USA) for the ESIMS spectra and with a LTQ (linear ion trap) Orbitrap XL hybrid mass spectrometer (Thermo Fisher Scientific, Bremen, Germany) for the HRMS-ESI (high resolution mass spectrometry) spectra. For the HRMS analyses the signal for the isotopes with the highest prevalence was given and calculated ( $^{35}\text{Cl}$ ,  $^{79}\text{Br}$ ).

$^1\text{H}$  NMR and  $^{13}\text{C}$  NMR spectra were taken on a Varian Inova 500 using deuterated chloroform and deuterated DMSO as solvent. Chemical shifts are referenced to the residual solvent signals.

The following abbreviations and formulas for solvents and reagents were used: dimethylformamide (DMF), dimethylsulfoxide (DMSO), tetrahydrofuran (THF), N,N-diisopropylethylamine (DIPEA) and



hydrochloric acid (HCl), methanol (MeOH), water (H<sub>2</sub>O), sodium hydroxide (NaOH), dichloromethane(DCM), sodium triacetoxyborohydride (Na(AcO)<sub>3</sub>BH), lithium hydroxide monohydrate (LiOH.H<sub>2</sub>O), (PyBOP), O-(Tetrahydro-2H-pyran-2-yl)hydroxylamine (H<sub>2</sub>NOTHP), ethanol (EtOH), benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate (PyBOP), Potassium carbonate (K<sub>2</sub>CO<sub>3</sub>),Potassium iodide(KI).

## General synthesis methods

### Method A: reductive amination of primary amines

The amine (1 eq) was dissolved in dichloromethane (20 ml). The aldehyde (0.95 eq) was added dropwise, and the mixture was stirred at room temperature for 30 min. Afterwards sodium triacetoxyborohydride (2 eq) was added and the mixture was stirred over-night at room temperature. Methanol (5 ml) was added, and the solvents were evaporated under reduced pressure. The products were purified with MPLC using chloroform/methanol as eluent.

### Method B: reductive amination of secondary amines

The amine (1 eq) was dissolved in ethanol (15 ml). The aldehyde (5 eq) was added and the mixture was stirred at room temperature for 15 min. Afterwards sodium triacetoxyborohydride (5 eq) was added and the mixture was stirred over-night at room temperature. Sodium triacetoxyborohydride (5 eq) was added and the reaction was stirred over night at room temperature. Methanol (5 ml) was added, and the solvents were evaporated under reduced pressure. The products were purified with MPLC using chloroform/methanol as eluent.

### Method C: alkylation of secondary amines

The amine (1 eq) was solved in dimethylformamide (6 ml). Potassium carbonate (4 eq) was added, the mixture was stirred for 30 min at room temperature. Afterwards potassium carbonate (4 eq), the alkyl bromide (3 eq) and potassium iodide (1 spatula tip) were added. The mixture was stirred for 72 h at room temperature. The solvent was evaporated under reduced pressure. Further purifications were not performed.

### Method D: ester hydrolysis with NaOH

The ester (1 eq) was dissolved in methanol (50 ml) and 1M NaOH<sub>aq</sub> (5 ml) and refluxed for 4 h. The mixture was neutralized with 1M HCl<sub>aq</sub> and evaporated under reduced pressure. The products were purified with MPLC using chloroform/methanol as eluent.

#### Method E: ester hydrolysis with LiOH

A mixture of the appropriate ester (1 eq) and lithium hydroxide monohydrate (2 eq) in 1:1 mixture of tetrahydrofuran and water (50 ml) was stirred over night at room temperature. The solvents were evaporated under reduced pressure. The products were purified with MPLC using chloroform/methanol as eluent.

#### Method F: synthesis of THP-protected hydroxamic acids


The appropriate carboxylic acid (1 eq) was dissolved in tetrahydrofuran (25 ml). *N,N*-diisopropylethylamine (12 eq), benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate (3 eq) and *O*-(tetrahydro-2H-pyran-2-yl)hydroxylamine (3 eq) were added. The mixture was stirred at room temperature for 72 h. The solvents were evaporated under reduced pressure. The products were purified with MPLC using chloroform/methanol as eluent.

#### Method G: THP-deprotection

The THP protected hydroxamic acid (1 eq) was solved in tetrahydrofuran (25 ml), water (12.5 ml) and 1M HCl<sub>aq</sub> (25 drops). The mixture was stirred over night at room temperature. The solvents were evaporated under reduced pressure. The products were purified with MPLC using chloroform/methanol as eluent.

### **Characterization of the final compounds**

#### **4a 4-[(benzylamino)methyl]-benzhydroxamic acid**




The title compound was synthesized from methyl 4-(aminomethyl)benzoate and benzaldehyde using method A, followed by hydrolysis of the ester product using method D. The hydroxamic acid was synthesized using method F followed by method G.

HRMS m/z: 257.1287 [M+H]<sup>+</sup>

<sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) δ = 4.12 (s, 4H), 7.39 (s, 3H), 7.58 (m, 4H), 7.77 (s, 2H), 9.07 (s, 1H), 10.05 (s, 2H), 11.34 (s, 1H).

Purity: 96% (HPLC)

**4b** 4-[[[(thiophen-2-ylmethyl) amino]methyl]benzhydroxamic acid




The title compound was synthesized from methyl 4-(aminomethyl)benzoate and 2-thiophenecarboxaldehyde using method A, followed by hydrolysis of the ester product using method D. The hydroxamic acid was synthesized using method F followed by method G.

HRMS m/z: 263.0850 [M+H]<sup>+</sup>

<sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>): δ = 4.10 (s, 2H), 4.30 (s, 2H), 7.08 (dd, J<sub>1</sub> = 3,6 Hz, J<sub>2</sub> = 5,2 Hz, 1H), 7.27 (d, J = 2.4 Hz, 1H), 7.56 (m, 3H), 7.75 (m, 2H), 8.98 (m, 3H), 11.26 (s, 1H).

Purity 97% (HPLC)

**4c** 4-[[[(thiophen-3-ylmethyl)amino]methyl]benzhydroxamic acid




The title compound was synthesized from methyl 4-(aminomethyl)benzoate and 3-thiophenecarboxaldehyde using method A, followed by hydrolysis of the ester product using method D. The hydroxamic acid was synthesized using method F followed by method G.

HRMS m/z: 263.0845 [M+H]<sup>+</sup>

<sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) δ = 4.14 (s, 4H), 7.33 (dd, J<sub>1</sub> = 1.6 Hz, J<sub>2</sub> = 5.2 Hz, 1H), 7.59 (m, 3H), 7.71 (dd, J<sub>1</sub> = 1.2 Hz, J<sub>2</sub> = 2.8 Hz, 1H), 7.76 (m, 2H), 9.09 (s, 1H), 9.83 (m, 2H), 11.30 (s, 1H).

Purity 98% (HPLC)

#### 6a 4-(piperidin-1-ylmethyl)benzhydroxamic acid




The title compound was synthesized from 4-(piperidin-1-yl) methyl)benzoic acid using method F followed by method G.

HRMS m/z: 235.1442 [M+H]<sup>+</sup>

<sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) δ = 1.17 (m, 6H), 1.55 (s, 1H), 1.80 (s, 3H), 3.00 (m, 2H), 7.44 (s, 1H), 7.89 (s, 1H), 8.21 (s, 2H).

Purity 70% (HPLC)

#### 6b 4-[(N-methylpiperazin-1-yl)methyl]benzhydroxamic acid




The title compound was synthesized from 4-[(N-methylpiperazinyl)methyl]benzoic acid using method F followed by method G.

HRMS m/z: 250.1551 [M+H]<sup>+</sup>

<sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) δ = 2.77 (s, 3H), 3.41 (m, 8H), 4.32 (s, 2H), 7.69 (m, 2H), 7.79 (m, 2H), 11.30 (s, 1H).

Purity 100% (HPLC)

**10a** (*E*)-3-(1-phenethylpiperidin-4-yl)acrylhydroxamic acid




The title compound was synthesized from ethyl (*E*)-3-(piperidin-4-yl)acrylate and (2-bromoethyl)benzene using Method C, followed by hydrolysis of the ester product using method E. The hydroxamic acid was synthesized using method F followed by method G.

HRMS m/z: 275.1755 [M+H]<sup>+</sup>

<sup>1</sup>H-NMR (400 MHz, DMSO-d<sub>6</sub>) δ = 1.77 (m, 2H), 1.87 (d, J<sub>1</sub> = 13.6 Hz, 2H), 2.69 (m, 1H), 2.97 (m, 2H), 3.09 (m, 2H), 3.20 (m, 2H), 3.56 (d, J<sub>1</sub> = 11.6 Hz, 2H), 5.78 (d, J<sub>1</sub> = 15.6 Hz, 1H), 6.56 (dd, J<sub>1</sub> = 6.0 Hz, J<sub>2</sub> = 15.6 Hz, 1H), 7.25 (m, 3H), 7.32 (m, 2H), 8.96 (s, 1H), 10.74 (s, 1H).

Purity 96% (HPLC)

**10b** (*E*)-3-{1-[2-(1*H*-indol-3-yl)ethyl]piperidin-4-yl}acrylhydroxamic acid




The title compound was synthesized from ethyl (*E*)-3-(piperidin-4-yl)acrylate and 3-(2-bromoethyl)indole using Method C, followed by hydrolysis of the ester product using method E. The hydroxamic acid was synthesized using method F followed by method G.

HRMS  $m/z$ : 314.1862 [M+H]<sup>+</sup>

<sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>)  $\delta$  = 1.59 (m, 2H), 1.92 (d,  $J_1$  = 13.2 Hz, 2H), 2.40 (m, 1H), 3.02 (m, 2H), 3.11 (m, 2H), 3.31 (m, 2H), 3.65 (d,  $J_1$  = 11.6 Hz, 2H), 5.77 (d, 1H), 6.59 (dd,  $J_1$  = 6.0 Hz,  $J_2$  = 15.6 Hz, 1H), 7.00 (t,  $J_1$  = 7.2 Hz, 1H), 7.09 (t,  $J_1$  = 6.8 Hz, 1H), 7.23 (s, 1H), 7.35 (d,  $J_1$  = 8.0 Hz, 1H), 7.57 (d,  $J_1$  = 7.6 Hz, 1H), 9.67 (s, 1H), 10.98 (s, 1H).

Purity 97% (HPLC)

**10c** (*E*)-3-[1-(naphthalen-1-ylmethyl)piperidin-4-yl]acrylhydroxamic acid




The title compound was synthesized from ethyl (*E*)-3-(piperidin-4-yl)acrylate and 1-(bromomethyl)naphthalene using Method C, followed by hydrolysis of the ester product using method E. The hydroxamic acid was synthesized using method F followed by method G.

HRMS  $m/z$ : 311.1755 [M+H]<sup>+</sup>

$^1\text{H}$  NMR (400 MHz, DMSO- $d_6$ )  $\delta$  = 1.55 (m, 2H), 1.75 (m, 2H), 2.26 (m, 1H), 3.12 (m, 2H), 5.77 (d,  $J_1$  = 15.6 Hz, 1H), 6.55 (m, 1H), 7.56 (m, 4H), 7.94 (m, 2H), 8.34 (s, 1H), 8.87 (s, 1H), 10.69 (s, 1H).

Purity 95% (HPLC)

**10d** (*E*)-3-[1-(3-chlorobenzyl)piperidin-4-yl]acrylhydroxamic acid




The title compound was synthesized from ethyl (*E*)-3-(piperidin-4-yl)acrylate and 3-chlorobenzyl bromide using Method C, followed by hydrolysis of the ester product using method E. The hydroxamic acid was synthesized using method F followed by method G.

HRMS  $m/z$ : 295.1205  $[\text{M}+\text{H}]^+$

$^1\text{H}$  NMR (400 MHz,  $\text{CD}_3\text{OD}$ )  $\delta$  = 1.67 (m, 2H), 1.94 (d,  $J_1$  = 10.0 Hz, 2H), 2.43 (m, 2H), 2.84 (m, 2H), 2.98 (s, 1H), 4.12 (s, 2H), 5.83 (d,  $J_1$  = 12.4 Hz, 1H), 6.73 (dd,  $J_1$  = 4.8 Hz,  $J_2$  = 12.0 Hz, 1H), 7.45 (m, 3H), 7.54 (s, 1H), 8.41 (s, 1H).

Purity 99% (HPLC)

**10e** (*E*)-3-(1-benzylpiperidin-4-yl)acrylhydroxamic acid



The title compound was synthesized from ethyl (*E*)-3-(piperidin-4-yl)acrylate and benzyl bromide using Method C, followed by hydrolysis of the ester product using method E. The hydroxamic acid was synthesized using method F followed by method G.


HRMS  $m/z$ : 261.1595  $[\text{M}+\text{H}]^+$



$^1\text{H}$  NMR (400 MHz,  $\text{CD}_3\text{OD}$ )  $\delta$  = 2.02 (m, 2H), 2.29 (m, 2H), 2.86 (m, 2H), 3.35 (s, 1H), 3.51 (d,  $J_1 = 10.4$  Hz, 2H), 4.42 (s, 2H), 5.85 (d,  $J_1 = 12.4$  Hz, 1H), 6.73 (dd,  $J_1 = 4.0$  Hz,  $J_2 = 12.4$  Hz, 1H), 7.47 (s, 1H), 7.54 (m, 1H), 7.55 (m, 2H), 7.60 (m, 1H).

Purity 96% (HPLC)

**10f** (*E*)-3-[1-(4-methylbenzyl) piperidin-4-yl]acrylhydroxamic acid




The title compound was synthesized from ethyl (*E*)-3-(piperidin-4-yl)acrylate and 4-methylbenzyl bromide using Method C, followed by hydrolysis of the ester product using method E. The hydroxamic acid was synthesized using method F followed by method G.

HRMS  $m/z$ : 275.1751 [ $\text{M}+\text{H}$ ] $^+$

$^1\text{H}$  NMR (400 MHz,  $\text{CD}_3\text{OD}$ )  $\delta$  = 1.65 (m, 2H), 1.96 (d,  $J_1 = 10.4$  Hz, 2H), 2.37 (s, 3H), 2.44 (s, 1H), 2.89 (m, 2H), 3.37 (d,  $J_1 = 9.6$  Hz, 2H), 4.13 (s, 2H), 5.86 (d,  $J_1 = 12.4$  Hz, 1H), 6.71 (dd,  $J_1 = 5.2$  Hz,  $J_2 = 12.4$  Hz, 1H), 7.32 (dd,  $J_1 = 6.4$  Hz,  $J_2 = 26.0$  Hz, 4H), 8.42 (s, 1H).

Purity 91% (HPLC)

**10g** (*E*)-3-{1-[(1,1'-biphenyl)-4-ylmethyl]piperidin-4-yl} acrylhydroxamic acid




The title compound was synthesized from ethyl (*E*)-3-(piperidin-4-yl)acrylate and 4-brommethylbiphenyl using Method C, followed by hydrolysis of the ester product using method E. The hydroxamic acid was synthesized using method F followed by method G.

HR-MS m/z: 337.1908 [M+H]<sup>+</sup>

<sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ = 1.72 (m, 2H), 2.01 (m, 2H), 2.50 (s, 1H), 3.04 (t, J<sub>1</sub> = 9.6 Hz, 2H), 3.48 (d, J<sub>1</sub> = 10.4 Hz, 2H), 4.31 (s, 2H), 5.86 (d, J<sub>1</sub> = 12.4 Hz, 1H), 6.74 (dd, J<sub>1</sub> = 5.2 Hz, J<sub>2</sub> = 12.4 Hz, 1H), 7.38 (m, 1H), 7.47 (m, 2H), 7.59 (m, 2H), 7.64 (m, 2H), 7.74 (m, 2H), 8.33 (s, 1H).

HPLC: rt 10.29 min (97.47 %)

**13a** (*E*)-3-{1-[benzothiophen-3-ylmethyl]piperidin-4-yl} acrylhydroxamic acid




The title compound was synthesized from ethyl (*E*)-3-(piperidin-4-yl)acrylate and 1-Benzothiophen-3-carboxaldehyde using Method B, followed by hydrolysis of the ester product using method E. The hydroxamic acid was synthesized using method F followed by method G.

HRMS m/z: 317.1319 [M+H]<sup>+</sup>

<sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) δ = 1.82 (m, 4H), 2.32 (m, 1H), 3.08 (m, 4H), 4.55 (s, 2H), 5.74 (d, J<sub>1</sub> = 15.6 Hz, 1H), 6.55 (dd, J<sub>1</sub> = 6.0 Hz, J<sub>2</sub> = 15.6 Hz, 1H), 7.44 (m, 2H), 8.06 (d, J<sub>1</sub> = 8.0 Hz, 1H), 8.18 (d, J<sub>1</sub> = 7.6 Hz, 1H), 8.28 (s, 1H), 8.91 (s, 1H), 10.74 (s, 1H).

HPLC: rt 4.24 min (95.82 %)

**13b** (*E*)-3-{1-[(1-methylindol-3-yl)methyl]piperidin-4-yl} acrylhydroxamic acid




The title compound was synthesized from ethyl (*E*)-3-(piperidin-4-yl)acrylate and 1-Methylindol-3-carboxaldehyde using Method B, followed by hydrolysis of the ester product using method E. The hydroxamic acid was synthesized using method F followed by method G.

HR-MS  $m/z$ : 314.1865  $[M+H]^+$

$^1\text{H}$  NMR (400 MHz, DMSO- $d_6$ )  $\delta$  = 1.29 (m, 2H), 1.59 (d,  $J_1$  = 10.8 Hz, 2H), 1.95 (m, 2H), 2.37 (m, 1H), 2.85 (d,  $J_1$  = 11.2 Hz, 2H), 3.59 (s, 2H), 3.73 (s, 3H), 5.73 (d,  $J_1$  = 15.6 Hz, 1H), 6.55 (dd,  $J_1$  = 6.8 Hz,  $J_2$  = 15.6 Hz, 1H), 7.19 (s, 1H), 7.34 (d,  $J_1$  = 8.4 Hz, 1H), 7.43 (m, 1H), 7.56 (m, 1H), 7.59 (d,  $J_1$  = 7.6 Hz, 1H), 10.76 (s, 1H).

HPLC: rt 3.94 min (97.64 %)

**13c** (*E*)-3-[1-(4-chlorobenzyl)piperidin-4-yl]acrylhydroxamic acid



The title compound was synthesized from ethyl (*E*)-3-(piperidin-4-yl)acrylate and 4-chlorobenzaldehyde using Method B, followed by hydrolysis of the ester product using method E. The hydroxamic acid was synthesized using method F followed by method G.

HRMS  $m/z$ : 295.1212  $[M+H]^+$

$^1\text{H}$  NMR (400 MHz, DMSO- $d_6$ )  $\delta$  = 1.51 (m, 2H), 1.86 (d,  $J_1$  = 15.6 Hz, 2H), 2.36 (m, 1H), 2.92 (m, 2H), 3.35 (d,  $J_1$  = 12.4 Hz, 2H), 4.28 (s, 1H), 5.74 (d,  $J_1$  = 15.6 Hz, 1H), 6.53 (dd,  $J_1$  = 6.4 Hz,  $J_2$  = 15.6 Hz, 1H), 7.53 (m, 4H), 8.59 (s, 1H), 10.60 (s, 1H).

Purity 99% (HPLC)

### **In vitro HDAC inhibitory activity**

*HDAC1, HDAC6 and HDAC8*

The in vitro testing on recombinant HDACs were performed as previously described.<sup>34</sup> Recombinant human HDAC1 and -6 were purchased from BPS Biosciences. The enzyme inhibition was determined by using a reported homogenous fluorescence assay.<sup>35</sup> The enzymes were incubated for 90 min at 37°C, with the fluorogenic substrate ZMAL (Z-(Ac)Lys-AMC) in a concentration of 10.5 mM and increasing concentrations of inhibitors with subsequent addition of 60 mL of buffer containing trypsin (1 mg/ml) and TSA (2.75 mM) and further incubation for 20 min at 37°C. Fluorescence intensity was measured at an excitation wavelength of 390 nm and an emission wavelength of 460 nm in a microtiter plate reader (BMG Polarstar).

Recombinant hHDAC8 was produced by Romier et al. in Strasbourg.<sup>36</sup> The HDAC8 activity assays were performed according to the commercial HDAC8 Fluorometric Drug Discovery Kit [Fluor de Lys(R)-HDAC8, BML-KI178] corresponding to the manufacturer's instructions. As substrate a tetrapeptide connected to aminomethylcoumarin (AMC) H<sub>2</sub>N-Arg- His-Lys(Ac)-Lys(Ac)-AMC was synthesized as previously described.<sup>34</sup> The enzyme was incubated for 90 min at 37 °C, with a substrate concentration of 50 µM and increasing concentrations of inhibitors. The stop-solution containing inhibitor, to stop the hHDAC8 activity, and Trypsin, to release the AMC, was added. The solution was incubated for 20 min at 37 °C to develop the assay. Fluorescence intensity was measured at an excitation wavelength of 355 nm and an emission wavelength of 460 nm in a microtiter plate reader (BMG Polarstar).

#### *drHDAC10*

Enzyme was obtained as described previously.<sup>23</sup> All stock solutions were prepared in DMSO; NDA (16 mM) and Ac-spermidine-AMC (10 mM). Compounds for testing were solved and diluted to 12-fold higher than test concentration in DMSO. Ac-spermidine-AMC stock solutions was diluted with assay buffer (20 mM Na<sub>2</sub>HPO<sub>4</sub>, pH 7.9, 100 mM NaCl, 0.25 mM EDTA, 10 % (v/v) glycerol, 10 mM Mesna, 0.01 % TWEEN 20) to 126 µM. For assay determination stop solution was prepared, containing 5 µL

NDA (16 mM), and 190  $\mu$ L borat buffer (100 mM boric acid, pH 9.5) per well. Directly before using enzyme solution (0.0054 mg/ml) was prepared in assay buffer.

The assay was performed in black 96-well plates (PerkinElmer, OptiPlate<sup>TM</sup>-96 F). Assay buffer was presented in the plate, 55  $\mu$ L for the blank, 45  $\mu$ L for the blank containing enzyme solution, 50  $\mu$ L for the negative control and 40  $\mu$ L for the positive control and test compounds. 5  $\mu$ L of DMSO were added to the wells of blanks, positive and negative control. Corresponding to the DMSO 5  $\mu$ L of increasing concentrations of inhibitors in DMSO were added to the relevant wells. After adding 10  $\mu$ L of enzyme solution (12 nM final assay concentration) to blank containing enzyme, positive control and test compounds, 5  $\mu$ L Ac-spermidine-AMC solution (10.5  $\mu$ M final assay concentration) were added to negative control, positive control and test compounds. The plate was incubated for 25 min at 25 °C. Before measuring fluorescence (POLARstar plate reader,  $\lambda_{\text{ex}} = 330$  nm,  $\lambda_{\text{em}} = 390$  nm) each well was filled with 200  $\mu$ L stop solution.

#### *IC<sub>50</sub> calculation*

Inhibition was measured at increasing concentration and IC<sub>50</sub> was calculated by nonlinear regression with Origin 9.0G software.

#### *Cytotoxicity assay*

To determine the cytotoxicity of the developed compounds, a human epithelial kidney cell line (HEK293) was used. HEK293 cells (DSMZ Braunschweig, ACC305) were incubated at 37 °C in a humidified incubator with 5% CO<sub>2</sub> in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% fetal calf serum and 5mM glutamine. Cells were seeded out at  $1.5 \times 10^3$  cells per well in a 96-well cell culture plate (TPP, Switzerland). The compounds were added immediately to the medium at 50  $\mu$ M. After 24 h, AlamarBlue reagent (Invitrogen, CA) was added according to the manufacturer's instructions and incubated for 21 h before samples were analyzed. Detection of viable cells, which convert the resazurine reagent into the highly fluorescent resorufin, was performed by using a

FLUOstarOPTIMA microplate reader (BMG Labtec) and the following filter set: Ex 530 nm/Em 590 nm. Measurements were performed in triplicate and data are means with standard deviation < 14%. As a positive control daunorubicin was used and an IC<sub>50</sub> value of 12.55 ± 0.07 μM was obtained.

### *Molecular docking*

The available X-ray structures of drHDAC10 in complex with different inhibitors as listed in Table 4 were downloaded from the Protein Databank (PDB, [www.rcsb.org](http://www.rcsb.org)). Protein preparation was done using the protein preparation wizard implemented in Schroedinger version 2019.1 by adding hydrogen atoms, assigning protonation states and minimizing the protein using the OPLS force field implementing the default settings. Ligands structures were generated in MOE [Molecular Operating Environment (MOE), 2020.01; Chemical Computing Group Inc., 1010 Sherbooke St. West, Suite #910, Montreal, QC, Canada, H3A 2R7, 2018]. The ligands were subsequently prepared for docking using the LigPrep tool as implemented in Schroedinger's software (version 2019.1) and energy minimized using the OPLS3e force field. 25 conformers of all ligands were subsequently generated with ConfGen. Docking of the generated conformers into the prepared protein structures was performed using the program Glide (Schroedinger-release 2019.1) in the Standard Precision mode. To test the ability of the docking approach to correctly reproduce the drHDAC10-inhibitor complexes we docked the cocrystallized inhibitors using the described docking setup. For all complexes the docking setup resulted in docking poses with root mean square deviation (RMSD) values below 2.0 Å (**Table 4**) for the top-ranked solution (Glidescore SP) with the exception of one structure (PDB ID 6UIM). If considering all docking solutions RMSD values below 0.9 Å were determined for all ligands indicating that the docking setup is able to predict the interaction of the diverse inhibitors correctly. The novel inhibitors were subsequently docked to drHDAC10 (PDB ID: 5TD7) and humanized HDAC10 (PDB ID: 6VNQ) as representative protein structures.

**Table 4.** Validation of docking setup for HDAC10-inhibitor complexes from the Protein DataBank

PDB ID	Cocryst. ligand	Enzyme (Resolution)	RMSD (Å) of top ranked pose	Best RMSD (Å) among top-5 ranked poses	Best RMSD (Å) and docking rank
5TD7	7-[(3-aminopropyl)amino]-1,1,1-trifluoroheptane-2,2-diol	drHDAC10 (2.65 Å)	1.91	1.78	0.89 (119)
6UFN	7-[(3-aminopropyl)amino]heptan-2-one	drHDAC10 (2.70 Å)	1.22	0.84	0.66 (292)
6UFO	7-[(3-aminopropyl)amino]-1-methoxyheptan-2-one	drHDAC10 (2.68 Å)	1.08	1.07	0.51 (283)
6UHV	6-[(3-aminopropyl)amino]-N-hydroxyhexanamide	drHDAC10 (2.53 Å)	1.25	1.15	0.75 (110)
6UHU	5-[(3-aminopropyl)amino]pentyl boronic acid	drHDAC10 (2.80 Å)	1.60	1.45	0.72 (166)
6UII	5-[(3-aminopropyl)amino]pentane-1-thiol	drHDAC10 (2.65 Å)	0.81	0.59	0.59 (3)
6UIJ	S-{5-[(3-aminopropyl)amino]pentyl} thioacetate	drHDAC10 (2.90 Å)	1.06	1.05	0.51 (117)
6UIL	7-[(3-aminopropyl)amino]-1,1,1-trifluoroheptan-2-one	drHDAC10 (2.85 Å)	0.79	0.78	0.57 (216)
6UIM	7-[(3-aminopropyl)amino]-2-oxoheptyl} thioacetate	drHDAC10 (2.75 Å)	2.93	1.31	0.69 (62)
6VNQ	bishydroxamate	humanized drHDAC10 (2.05 Å)	0.35	0.35	0.32 (16)
6WBQ	hydroxamate	humanized drHDAC10 (2.00 Å)	0.54	0.54	0.54 (1)
6WDV	hydroxamate	humanized drHDAC10 (2.40 Å)	0.53	0.53	0.47 (26)
6WDW	hydroxamate	humanized drHDAC10 (2.20 Å)	0.35	0.39	0.34 (59)
6WDX	hydroxamate	humanized drHDAC10 (2.65 Å)	0.62	0.52	0.36 (30)
6WDY	hydroxamate	humanized drHDAC10 (2.65 Å)	0.62	0.58	0.52 (6)
7KUQ	acetyl-spermidine	drHDAC10 Y307F mutant (2.10 Å)	1.16	0.44	0.24 (55)
7KUR	acetyl-putrescine	drHDAC10 Y307F	0.73	0.73	0.18 (64)

		mutant (2.10 Å)			
7KUS	acetyl-spermidine	drHDAC10 H137A mutant (2.00 Å)	1.09	1.09	0.62 (128)
7KUT	acetyl-putrescine	drHDAC10 H137A mutant (2.05 Å)	0.69	0.64	0.25 (97)

#### *PAINS filter*

All the herein described compounds were filtered for pan-assay interference compounds (PAINS).<sup>37</sup> For this purpose, PAINS1, PAINS2 and PAINS3 filters, as implemented in Schroedinger's Canvas program, were employed. None of the compounds was flagged as a PAIN.

#### *Immunoblot*

Immunoblots were performed as described.<sup>27, 38</sup> Antibodies were: GAPDH (#ab128915) from Abcam, Cambridge, U.K.;  $\beta$ -actin (#sc-47778), HDAC10 (#sc-54215), HSP70 (#sc-66048), p62/SQSTM1 (#sc-25575) from Santa Cruz, Heidelberg, Germany; ac-H3 (#06-599) from Millipore-Merck, Darmstadt, Germany; ac-Tubulin (#T7451) from Sigma-Aldrich, Darmstadt, Germany. As protein ladders served the prestained Scientific™ PageRuler™ (#26617) and the PageRuler™ Plus (#26620) from Thermo Fisher, Braunschweig, Germany.

#### *Detection of modulation of autophagy*

Modulation of autophagy was detected with techniques that we described in<sup>39</sup> using the Cyto-ID® Autophagy Detection Kit (Enzo Life Science, Lörrach, Germany). In brief, MV4-11 cells were treated with 2 to 15  $\mu$ M **13b** or **10c** as well as 10  $\mu$ M chloroquine and incubated for 24 h at 37°C, 5 % CO<sub>2</sub>. Cells were then harvested, washed with PBS (phosphate-buffered saline), and stained with Cyto-ID® Green (1:1000 in phenol-red free RPMI, supplemented with 5% FCS, 30 min, 37 °C). After incubation



time, cells were washed with PBS twice and measured via flow cytometry using a FACSCanto™ II (BD Biosciences, Heidelberg, Germany). Analysis was done using the FACSDiva software (BD Biosciences).

#### *Annexin-V-FITC / PI Flow Cytometry measurements*

Detection of cell death was done as described,<sup>38</sup> MV4-11 cells were treated with 2 - 15  $\mu\text{M}$  **13b** or **10c** or 5  $\mu\text{M}$  MS-275 and incubated for 24 h at 37°C, 5 % CO<sub>2</sub>. Cells were then harvested, washed with PBS, and resuspended in 50  $\mu\text{L}$  1x annexin-V binding buffer containing 2.5  $\mu\text{L}$  annexin V-FITC (Miltenyi Biotec, Bergisch Gladbach, Germany). Samples were incubated for minimum 20 min in the dark at room temperature. Then, PI (50  $\mu\text{g}/\text{mL}$ ) diluted 1:44 in 440  $\mu\text{L}$  1x annexin-V binding buffer were added. Samples were then subjected to flow cytometry using a FACSCanto™ II. Analysis was performed using the FACSDiva software (BD Biosciences).

#### *LysoTracker Assay*

Human neuroblastoma SK-N-BE(2)-C cells (European Collection of Authenticated Cell Cultures, ECACC, Salisbury, UK) were seeded into 6-well dishes at a density of  $1.5 \times 10^5$  cells per well and treated for 24 h with compounds of interest. Cells were stained for 1 h with LysoTracker Red DND-99 (50 nM) in medium under standard cell culture conditions. Cells were washed with ice-cold RPMI without phenol-red and trypsinized for 3 min at 37 °C. Detached cells were centrifuged for 3 min at 8600g and re-suspended in ice-cold RPMI without phenol-red. Mean LysoTracker fluorescence was quantified on a BD FACSCanto II platform using the PE filter setting.

## References

1. San Jose-Eneriz E, Gimenez-Camino N, Agirre X, Prosper F. HDAC Inhibitors in Acute Myeloid Leukemia. *Cancers (Basel)* **2019**, *11* (11).
2. Li G, Tian Y, Zhu WG. The Roles of Histone Deacetylases and Their Inhibitors in Cancer Therapy. *Front Cell Dev Biol* **2020**, *8*, 576946.
3. Krämer OH. HDAC2: a critical factor in health and disease. *Trends Pharmacol Sci* **2009**, *30* (12), 647-55.
4. Beyer M, Romanski A, Mustafa AM, Pons M, Buchler I, Vogel A, et al. HDAC3 Activity is Essential for Human Leukemic Cell Growth and the Expression of beta-catenin, MYC, and WT1. *Cancers (Basel)* **2019**, *11* (10).
5. Nebbioso A, Carafa V, Conte M, Tambaro FP, Abbondanza C, Martens J, et al. c-Myc Modulation and Acetylation Is a Key HDAC Inhibitor Target in Cancer. *Clin Cancer Res* **2017**, *23* (10), 2542-55.
6. Oehme I, Linke JP, Bock BC, Milde T, Lodrini M, Hartenstein B, et al. Histone deacetylase 10 promotes autophagy-mediated cell survival. *Proc Natl Acad Sci U S A* **2013**, *110* (28), E2592-601.
7. Shinsky SA, Christianson DW. Polyamine Deacetylase Structure and Catalysis: Prokaryotic Acetylpolyamine Amidohydrolase and Eukaryotic HDAC10. *Biochemistry* **2018**, *57* (22), 3105-14.
8. Hai Y, Shinsky SA, Porter NJ, Christianson DW. Histone deacetylase 10 structure and molecular function as a polyamine deacetylase. *Nat Commun* **2017**, *8*, 15368.
9. Zhang D, Tang B, Xie X, Xiao Y-F, Yang S-M, Zhang J-W. The interplay between DNA repair and autophagy in cancer therapy. *Cancer biology & therapy* **2015**, *16* (7), 1005-13.
10. Jiang W, Chen X, Ji C, Zhang W, Song J, Li J, et al. Key Regulators of Autophagosome Closure. *Cells* **2021**, *10* (11), 2814.
11. Ridinger J, Koeneke E, Kolbinger FR, Koerholz K, Mahboobi S, Hellweg L, et al. Dual role of HDAC10 in lysosomal exocytosis and DNA repair promotes neuroblastoma chemoresistance. *Scientific reports* **2018**, *8* (1), 10039.
12. Obayashi H, Nagano Y, Takahashi T, Seki T, Tanaka S, Sakai N, et al. Histone deacetylase 10 knockout activates chaperone-mediated autophagy and accelerates the decomposition of its substrate. *Biochemical and biophysical research communications* **2020**, *523* (1), 246-52.
13. Powers J, Lienlaf M, Perez-Villarroel P, Deng S, Knox T, Villagra A, et al. Expression and Function of Histone Deacetylase 10 (HDAC10) in B Cell Malignancies. *Methods Mol Biol* **2016**, *1436*, 129-45.
14. Blum KA, Advani A, Fernandez L, Van Der Jagt R, Brandwein J, Kambhampati S, et al. Phase II study of the histone deacetylase inhibitor MGD0103 in patients with previously treated chronic lymphocytic leukaemia. *British journal of haematology* **2009**, *147* (4), 507-14.
15. Wang JC, Kafeel MI, Avezbakiyev B, Chen C, Sun Y, Rathnasabapathy C, et al. Histone deacetylase in chronic lymphocytic leukemia. *Oncology* **2011**, *81* (5-6), 325-9.
16. Van Damme M, Crompton E, Meuleman N, Mineur P, Bron D, Lagneaux L, et al. HDAC isoenzyme expression is deregulated in chronic lymphocytic leukemia B-cells and has a complex prognostic significance. *Epigenetics* **2012**, *7* (12), 1403-12.
17. Dahiya S, Beier UH, Wang L, Han R, Jiao J, Akimova T, et al. HDAC10 deletion promotes Foxp3(+) T-regulatory cell function. *Scientific reports* **2020**, *10* (1), 424.
18. Herbst-Gervasoni CJ, Steimbach RR, Morgen M, Miller AK, Christianson DW. Structural Basis for the Selective Inhibition of HDAC10, the Cytosolic Polyamine Deacetylase. *ACS Chem Biol* **2020**, *15* (8), 2154-63.
19. Gerald M, Morgen M, Sehr P, Steimbach RR, Moi D, Ridinger J, et al. Selective Inhibition of Histone Deacetylase 10: Hydrogen Bonding to the Gatekeeper Residue is Implicated. *J Med Chem* **2019**, *62* (9), 4426-43.
20. Kolbinger FR, Koeneke E, Ridinger J, Heimburg T, Muller M, Bayer T, et al. The HDAC6/8/10 inhibitor TH34 induces DNA damage-mediated cell death in human high-grade neuroblastoma cell lines. *Arch Toxicol* **2018**, *92* (8), 2649-64.

21. Li Y, Woster PM. Discovery of a new class of histone deacetylase inhibitors with a novel zinc binding group. *Medchemcomm* **2015**, *6* (4), 613-8.
22. Herbst-Gervasoni CJ, Christianson DW. X-ray Crystallographic Snapshots of Substrate Binding in the Active Site of Histone Deacetylase 10. **2021**, *60* (4), 303-13.
23. Heimbürg T, Kolbinger FR, Zeyen P, Ghazy E, Herp D, Schmidtkunz K, et al. Structure-Based Design and Biological Characterization of Selective Histone Deacetylase 8 (HDAC8) Inhibitors with Anti-Neuroblastoma Activity. **2017**, *60* (24), 10188-204.
24. Herp D, Ridinger J, Robaa D, Shinsky SA, Schmidtkunz K, Yesiloglu TZ, et al. First fluorescent acetylspermidine deacetylation assay for HDAC10 identifies inhibitors of neuroblastoma cell colony growth that increase lysosome accumulation. **2020**.
25. Beyer M, Henninger SJ, Haehnel PS, Mustafa A-HM, Gurdal E, Schubert B, et al. Identification of a highly efficient dual type I/II FMS-like tyrosine kinase inhibitor that disrupts the growth of leukemic cells. *Cell Chemical Biology* **2021**.
26. Silva MC, Nandi GA, Tentarelli S, Gurrell IK, Jamier T, Lucente D, et al. Prolonged tau clearance and stress vulnerability rescue by pharmacological activation of autophagy in tauopathy neurons. *Nat Commun* **2020**, *11* (1), 3258.
27. Beyer M, Kiweler N, Mahboobi S, Kramer OH. How to Distinguish Between the Activity of HDAC1-3 and HDAC6 with Western Blot. *Methods Mol Biol* **2017**, *1510*, 355-64.
28. Sellmer A, Stangl H, Beyer M, Grünstein E, Leonhardt M, Pongratz H, et al. Marbostat-100 Defines a New Class of Potent and Selective Antiinflammatory and Antirheumatic Histone Deacetylase 6 Inhibitors. *J Med Chem* **2018**, *61* (8), 3454-77.
29. Pons M, Reichardt CM, Hennig D, Nathan A, Kiweler N, Stocking C, et al. Loss of Wilms tumor 1 protein is a marker for apoptosis in response to replicative stress in leukemic cells. *Archives of Toxicology* **2018**, *92* (6), 2119-35.
30. Leonhardt M, Sellmer A, Krämer OH, Dove S, Elz S, Kraus B, et al. Design and biological evaluation of tetrahydro-beta-carboline derivatives as highly potent histone deacetylase 6 (HDAC6) inhibitors. *European journal of medicinal chemistry* **2018**, *152*, 329-57.
31. Pons M, Nagel G, Zeyn Y, Beyer M, Laguna T, Brachetti T, et al. Human platelet lysate as validated replacement for animal serum to assess chemosensitivity. *Altex* **2019**, *36* (2), 277-88.
32. Toutah K, Nawar N, Timonen S, Sorger H, Raouf YS, Bukhari S, et al. Development of HDAC Inhibitors Exhibiting Therapeutic Potential in T-Cell Prolymphocytic Leukemia. **2021**, *64* (12), 8486-509.
33. Zhang Y, Kwon S, Yamaguchi T, Cubizolles F, Rousseaux S, Kneissel M, et al. Mice lacking histone deacetylase 6 have hyperacetylated tubulin but are viable and develop normally. *Molecular and cellular biology* **2008**, *28* (5), 1688-701.
34. Ghazy E, Zeyen P, Herp D, Hügler M, Schmidtkunz K, Erdmann F, et al. Design, synthesis, and biological evaluation of dual targeting inhibitors of histone deacetylase 6/8 and bromodomain BRPF1. *European journal of medicinal chemistry* **2020**, *200*, 112338.
35. Stolfa DA, Stefanachi A, Gajer JM, Nebbioso A, Altucci L, Cellamare S, et al. Design, Synthesis, and Biological Evaluation of 2-Aminobenzanilide Derivatives as Potent and Selective HDAC Inhibitors. *ChemMedChem* **2012**, *7* (7), 1256-66.
36. Marek M, Kannan S, Hauser A-T, Moraes Mourão M, Caby S, Cura V, et al. Structural basis for the inhibition of histone deacetylase 8 (HDAC8), a key epigenetic player in the blood fluke *Schistosoma mansoni*. *PLoS pathogens* **2013**, *9* (9), e1003645.
37. Baell JB. chemistry, GHJOM, 2010.(2010) New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. *ACS Publications* *53*, 2719-40.
38. Pons M, Reichardt CM, Hennig D, Nathan A, Kiweler N, Stocking C, et al. Loss of Wilms tumor 1 protein is a marker for apoptosis in response to replicative stress in leukemic cells. *Arch Toxicol* **2018**, *92* (6), 2119-35.
39. Göder A, Mahendrarajah N, Krämer OH. Detection of Autophagy Induction After HDAC Inhibitor Treatment in Leukemic Cells. *Methods Mol Biol* **2017**, *1510*, 3-10.

